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28We previously demonstrated inhibition of ovalbumin-induced allergic airway hyper-responsiveness in
29the mouse using ES-62, a phosphorylcholine-containing glycoprotein secreted by the ﬁlarial nematode,
30Acanthocheilonema viteae. This inhibition correlated with ES-62-induced mast cell desensitisation,
31although the degree to which this reﬂected direct targeting of mast cells remained unclear as suppression
32of the Th2 phenotype of the inﬂammatory response, as measured by eosinophilia and IL-4 levels in the
33lungs, was also observed. We now show that inhibition of the lung Th2 phenotype is reﬂected in
34ex vivo analyses of draining lymph node recall cultures and accompanied by a decrease in the serum lev-
35els of total and ovalbumin-speciﬁc IgE. Moreover, ES-62 also suppresses the lung inﬁltration by neutro-
36phils that is associated with severe asthma and is generally refractory to conventional anti-inﬂammatory
37therapies, including steroids. Protection against Th2-associated airway inﬂammation does not reﬂect
38induction of regulatory T cell responses (there is no increased IL-10 or Foxp3 expression) but rather a
39switch in polarisation towards increased T-bet expression and IFNc production. This ES-62-driven switch
40in the Th1/Th2 balance is accompanied by decreased IL-17 responses, a ﬁnding in line with reports that
41IFNc and IL-17 are counter-regulatory. Consistent with ES-62 mediating its effects via IFNc-mediated
42suppression of pathogenic Th2/Th17 responses, we found that neutralising anti-IFNc antibodies blocked
43protection against airway inﬂammation in terms of pro-inﬂammatory cell inﬁltration, particularly by
44neutrophils and lung pathology. Collectively, these studies indicate that ES-62, or more likely small mol-
45ecule analogues, could have therapeutic potential in asthma, in particular for those subtypes of patients
46(e.g. smokers, steroid-resistant) who are refractory to current treatments.
47 2013 Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc.
48
49
50 1. Introduction
51 The incidence of asthma has doubled throughout developed
52 countries in recent decades (Umetsu et al., 2002) such that it is
53 now highly prevalent in many parts of the world. The Hygiene
54 Hypothesis aims to explain such an increased incidence as being
55 a consequence of improved sanitation and hygiene in modernised
56 societies, with the lack of infections in childhood preventing us
57 from developing an immune system that responds appropriately
58 to environmental antigens (Strachan, 1989). This has led to the
59 idea that the common exposure to parasite infections in develop-
60 ing countries protects individuals from atopic asthma, prevalent
61 in developed countries. This concept has been particularly investi-
62 gated with respect to helminth parasites and although the situa-
63 tion is by no means clear-cut (Leonardi-Bee et al., 2006),
64evidence can certainly be found to support a protective role for
65various platyhelminths and nematodes against asthma and allergy
66in animal models (Harnett and Harnett, 2010).
67Asthma is a chronic pulmonary disease characterised by airway
68inﬂammation, acute reversible airway obstruction, bronchial hyper-
69responsiveness and high levels of serum IgE (Holgate, 1999). The
70inﬂammation exhibited in asthma is generally accepted as being
71associated with a Th2 phenotype immune response with inﬁltrates
72of mast cells, eosinophils, macrophages and Th2 lymphocytes and
73their cytokines such as IL-5, IL-4 and IL-13 being present in in-
74creased amounts in the lungs (Busse and Lemanske, 2001). IL-5 in-
75duces eosinophils to differentiate from bone marrow progenitor
76cells and tomove to the lung and expand to forma local IL-4 produc-
77ing innate cell population. This further ampliﬁes the Th2 cytokine
78environment (Chen et al., 2004), resulting in increased IgE produc-
79tion (Bossie et al., 1987) which, when found on the surface of mast
80cells, is centrally involved in the pathogenesis of asthma (Busse and
81Lemanske, 2001). Collectively, these responses ultimately result in
82airway hyper-responsiveness (AHR) and remodelling.
0020-7519/$36.00  2013 Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc.
http://dx.doi.org/10.1016/j.ijpara.2012.12.001
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83 ES-62 is an immunomodulatory phosphorylcholine (PC)-glyco-
84 protein discovered in the rodent ﬁlarial nematode Acanthocheilo-
85 nema viteae (reviewed in Harnett and Harnett, 2010). ES-62
86 possesses a number of anti-inﬂammatory properties (Whelan
87 et al., 2000; Goodridge et al., 2001; Harnett and Harnett, 2010)
88 and consistent with this, we have shown that prophylactic ES-62
89 treatment is protective in a mouse model of Th1/Th17-mediated
90 inﬂammatory autoimmune disease, collagen-induced arthritis
91 (McInnes et al., 2003). Similarly, and consistent with the proposal
92 that helminth infections may protect from allergic inﬂammatory
93 diseases, we found that the anti-inﬂammatory actions of ES-62 ex-
94 tended to inhibition of inﬂammation exhibited in the lungs in the
95 murine ovalbumin (OVA)-induced model of allergic asthma
96 (Melendez et al., 2007). These data suggest that ES-62 has thera-
97 peutic potential in the treatment of asthma and hence it is impor-
98 tant to elucidate its mechanism of action. Prophylactic exposure to
99 ES-62 reduced disease severity and progression as indicated by his-
100 tological analysis of lung pathology and whole-body plethysmog-
101 raphy determination of airway hyper-reactivity and remodelling.
102 The protection observed in mice correlated with ES-62-induced
103 desensitisation of mast cells, which have been implicated in airway
104 remodelling (Carter and Bradding, 2011; Gilﬁllan and Beaven,
105 2011), and also with suppression of the Th2 phenotype of airway
106 inﬂammation, the latter as evidenced by reduced eosinophilia
107 and IL-4 levels in the lungs (Melendez et al., 2007). Therefore, we
108 investigated the mechanisms by which ES-62 acts to suppress
109 the Th2-mediated parameters of OVA-induced airway disease.
110 2. Materials and methods
111 2.1. Mice and reagents
112 Six to 8 week old female BALB/c mice were purchased from
113 Harlan Olac (Bicester, UK) and maintained at the Universities of
114 Glasgow and Strathclyde, UK. All procedures were conducted in
115 accordance with Home Ofﬁce, UK animal guidelines and with the
116 approval of the local ethical committees. Puriﬁed, endotoxin-free
117 ES-62 from the rodent ﬁlarial nematode, A. viteae, was produced
118 as described previously (Wilson et al., 2003). Neutralising anti-
119 IFNc antibodies were puriﬁed using Protein G Sepharose, Fast Flow
120 (Sigma Aldrich, Dorset, UK) from cell line XMG1.6, which was a
121 kind gift from Prof. Richard Grencis at the University of Manches-
122 ter, UK. The IgG isotype control (rat IgG1) was obtained from Bio X
123 Cell (West Lebanon, NH, USA).
124 2.2. Allergic airway model
125 Allergic airway inﬂammation was induced as described previ-
126 ously (McKay et al., 2004). Brieﬂy, 6–8 week old female BALB/c
127 mice were sensitised to OVA by i.p. injection of 100 lg of OVA in
128 200 ll of 1% alum (Alhydrogel; Brenntag Biosector, Fredriksund,
129 Denmark) on days 0 and 14. On day 14, mice were challenged by
130 the intranasal (i.n.) route with 50 lg of OVA in 30 ll of PBS (endo-
131 toxin-free, Lonza, Slough, UK) after anaesthesia was induced with
132 isoﬂurane. On days 25, 26 and 27 mice were anaesthetised and
133 re-challenged i.n. with 50 lg of OVA in 30 ll of PBS. Control mice
134 received PBS in place of OVA. Mice were subjected to euthanasia
135 on day 28 by lethal i.p. injection of avertin (1,1,1-tribromoethanol)
136 dissolved in iso-amyl alcohol and diluted 1 in 40 in PBS, and bron-
137 choalveolar lavage (BAL) and lung histology were performed as de-
138 scribed previously (Melendez et al., 2007). There were four
139 experimental groups denoted: PBS (control), ES-62, OVA and
140 OVA + ES-62. ES-62 and OVA + ES-62 mice received 2 lg of ES-62
141 in 100 ll of PBS, by s.c. injection in the scruff of the neck on days
142 2, 12, 25 and 27. Mice in the control and OVA groups received
143PBS on these days. The concentration of ES-62 used has been
144shown to be likely to give serum levels equivalent to those found
145for PC-containing molecules during ﬁlarial nematode infection of
146humans (Lal et al., 1987; Wilson et al., 2003). For the studies using
147neutralising anti-IFNc antibodies, mice in OVA and OVA + ES-62
148groups were i.p. injected with either 150 lg of anti-IFNc or isotype
149control IgG (both endotoxin free) in 150 ll of PBS on days 1, 15 and
15026. The control IgG antibody had no signiﬁcant effect on any of the
151OVA responses tested (results not shown).
1522.3. Ex vivo lymph node cultures
153Lungs were dissected and the peribronchial draining lymph
154nodes (DLNs; thoracic) harvested. DLN cells were cultured in RPMI
1551640 medium at 106 cells/ml with 10% FBS, penicillin (100 U/ml),
156streptomycin (100 lg/ml), L-glutamine (2 mM), 2-mercap-
157toethanol (50 lM), 1% non-essential amino acids and sodium pyru-
158vate (1 mM) (all from Gibco Life Technologies, Paisley, UK). Cells
159were cultured in medium alone or in medium containing antigen
160(OVA at 500 lg/ml) or concanavalin A (ConA, 3 lg/ml) for the
16172 h culture period. For proliferation analysis, cells were pulsed
162with [3H] thymidine (0.5 lCi/well; Amersham Pharmacia Biotech,
163Little Chalfont, UK) for the last 4 h of culture. For cytokine analysis,
164samples were centrifuged at the end of the culture period for 5 min
165at 400g and the supernatant removed and stored at 20 C until
166further analysis.
1672.4. Cytokine and antibody detection
168Cytokines in culture supernatants and serum were analysed
169using ELISA kits (BD Biosciences, Oxford, UK apart from that for
170IL-17: BioLegend Ltd., Cambridge, UK) or by employing the Lumin-
171ex system (also used for all other cytokines, chemokines and
172growth factors referred to) with a 20-Multiplex inﬂammatory cyto-
173kine kit (Biosource, Invitrogen, Paisley, UK) according to manufac-
174turers’ instructions. The lower limit of detection for all cytokines
175apart from IL-17 (15 pg/ml) was 20 pg/ml for ELISA and 5 pg/ml
176for IL-4 and IL-13, 10 pg/ml for IL-5, 15 pg/ml for IL-10 and 1 pg/
177ml for IL-17 and IFNc by Luminex. Bio-plex Manager software with
178ﬁve parametric curve ﬁtting was used for data analysis (Bio-Rad
179Laboratories Inc., USA). Total IgE and OVA-speciﬁc IgG1, IgG2a
180and IgE levels were measured in serum by ELISA (BD Biosciences,
181UK) following the manufacturer’s instructions using Maxisorp ELI-
182SA plates (Nunc, Roskilde, Denmark).
1832.5. In vitro dendritic cell (DC)-T cell cocultures
184Bone marrow-derived dendritic cells (bmDCs) were prepared as
185described previously (Goodridge et al., 2004, 2005). Brieﬂy, bone
186marrow cells were cultured in RPMI-1640 complete medium con-
187taining 2 mM L-glutamine, 50 U/ml of penicillin, 50 lg/ml of strep-
188tomycin, 10% FCS (Invitrogen) supplemented with 10% conditioned
189medium generated by the GM-CSF-secreting X63 myeloma cell line
190and 50 lM 2-mercaptoethanol, for 6 days at 37 C/5% CO2, with
191fresh medium supplied on day 4. On day 7, the loosely adherent
192immature bmDCs were harvested, pulsed with peptide antigen
193(Ag) (OVA332–339) and cocultured (2.5  104 cells) with OVA-spe-
194ciﬁc CD4+CD62L+ T cells (2  105 cells) from DO.11.10/BALB/c mice,
195puriﬁed using CD4+ T cell negative selection and enrichment for
196naïve CD62Lhigh cells (Miltenyi Biotec Ltd., UK) as described previ-
197ously (Whelan et al., 2000; Marshall et al., 2005). Cells were cocul-
198tured in a total volume of 1 ml of RPMI 1640 medium
199supplemented with 10% FBS, penicillin (100 U/ml), streptomycin
200(100 lg/ml), L-glutamine (2 mM), 2-mercaptoethanol (50 lM), 1%
201non-essential amino acids and sodium pyruvate (1 mM) in 24 well
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202 plates for 72 h at 37 C and 5% CO2. Cell supernatants were then re-
203 moved and stored at 20 C for future cytokine analysis.
204 2.6. Analysis of intracellular cytokine production and transcription
205 factor expression
206 Intracellular cytokine production was assessed using the Cell
207 Fixation and Permeabilisation solutions and protocols provided
208 by eBioscience (Hatﬁeld, UK) as described previously (Pineda
209 et al., 2012). Brieﬂy, DLN cells were stimulated with RPMI-1640
210 medium or 500 ng/ml of phorbol 12-myristate 13-acetate (PMA)
211 plus 500 ng/ml of ionomycin for 1 h before addition of 10 lg/ml
212 of Brefeldin A (eBioscience, UK) for 4 h at 37 C with 5% CO2. Cells
213 were stained with Fixable Viability Dye eFluor 780 (eBioscience)
214 prior to staining for cell surface phenotypic markers using anti-
215 CD4-PerCP or anti-CD8-FITC (both BD Pharmingen, UK). The cells
216 were then ﬁxed and permeabilised before staining with the
217 relevant cytokine-speciﬁc APC-conjugated (anti-IL-10: BD Pharm-
218 ingen; anti-IFNc and anti-IL-17: Biolegend) or PE-conjugated
219 (anti-IL4, BD Pharmingen) antibody. Intracellular FoxP3 and RORct
220 expression in LN cells was similarly analysed using the APC-conju-
221 gated FoxP3- and PE-conjugated RORct-speciﬁc antibodies, and
222 staining buffer sets and protocols from eBioscience.
223 2.7. Quantitative real time PCR (qRT-PCR)
224 qRT-PCR procedures were carried out according to the manufac-
225 turer’s instructions (Applied Biosystems, Carlsbad CA, USA). IL-4,
226 IL-17, IFNc and glyceraldehyde 3-phosphate dehydrogenase (GAP-
227 DH) levels were tested using Applied Biosystems assay kits,
228 Mm00445259_m1, Mm00439619_m1, Mm01168134_m1 and
229 Mm99999915_g1. All samples were examined in triplicate and
230 data analysed by StepOne software using the comparative CT
231 (DDCT) (Applied Biosystems) with values for samples being nor-
232 malised to the reference reporter GAPDH. Lungs stored in RNAlater
233 (Qiagen, Crawley, UK) were transferred into RTL plus buffer
234 (Qiagen) supplemented with b-mercaptoethanol and homogenised
235 with the TissueRuptor (Qiagen). The homogenate was then spun
236 down for 3 min at maximum speed and the lysate was used to
237 extract RNA using a RNAeasy plus kit (Qiagen). Up to 1 lg of
238 RNA was reverse transcribed using a High Capacity cDNA Reverse
239 Transcription Kit (Applied Biosystems) and 50 ng of RNA was used
240 per qRT-PCR.
241 2.8. Analysis of lineage-speciﬁc transcription factor expression in tissue
242 sections
243 Brieﬂy, tissue sections (6 lm) were incubated in acetone for
244 20 min, air dried and rehydrated with PBS containing 1% goat ser-
245 um before being incubated in blocking reagent containing 6% BSA,
246 10% goat serum and 1% Fc-block. For staining of transcription fac-
247 tors, 0.1% (v/v) TritonX (Sigma) was used whilst for IgE, 0.5% sapo-
248 nin was added to all buffers. Avidin solution (Vector Laboratories
249 Ltd., Peterborough, UK) was added for 15 min to block unmasked
250 endogenous biotin, then biotin solution (Vector Laboratories) was
251 added to block excess avidin. Puriﬁed or biotinylated primary anti-
252 bodies and isotype controls were added either for 1 h at room tem-
253 perature (surface marker) or overnight at 4 C (intracellular
254 staining). Fluorochrome conjugated secondary antibodies or strep-
255 tavidin conjugates were added for 1 h before mounting using
256 Vectashield. Images (20 magniﬁcation) were captured using a
257 Hammamatsu camera and analysed using Openlab imaging soft-
258 ware (Improvision, Coventry, UK). Quantitative laser scanning
259 cytometry (LSC) analysis was performed as described previously
260 (Adams et al., 2004; Morton et al., 2007) where standard cell con-
261 tours were set to determine individual transcription factor-positive
262T cells. Tissue maps were generated from these data and the num-
263ber and percentage of transcription factor-positive T cells located
264within the T cell area were determined using WinCyte software
265(CompuCyte Corp, Essex, UK).
2662.9. Statistical analysis
267Statistical analysis was determined by t-test and ANOVA or
268Kruskal–Wallis (non-parametric data) with Bonferroni or Dunn
269post-tests, respectively, as appropriate. P values of <0.05, <0.01
270and <0.001 were used to denote signiﬁcance.
2713. Results
2723.1. ES-62 suppresses inﬁltration of a heterogeneous population of
273inﬂammatory cells into the lungs of mice undergoing OVA-induced
274airway inﬂammation
275Prophylactic exposure to ES-62 in vivo reduces lung pathology
276and, speciﬁcally, eosinophilia in the mouse OVA-induced airway
277inﬂammation model, thereby protecting against OVA-induced
278hypersensitivity (Melendez et al., 2007). These results are now
279conﬁrmed and extended by our showing that in addition to pre-
280venting eosinophilic inﬂammation (Fig. 1A), ES-62 also signiﬁ-
281cantly prevented inﬁltration of the lungs by neutrophils (Fig. 1B)
282and lymphocytes (Fig. 1C). ES-62 also tended to reduce the num-
283bers of macrophages and total cells in the BAL ﬂuid (BALF) but this
284did not reach statistical signiﬁcance (Fig. 1D, E).
2853.2. ES-62 suppression of lung inﬂammation is associated with reduced
286local Th2 cytokine responses
287To address whether such protection reﬂects immunomodula-
288tion of polarised Th responses during OVA-induced airway inﬂam-
289mation, the effect of in vivo exposure to ES-62 on subsequent
290peribronchial DLN recall responses to OVA ex vivo was determined.
291Firstly, cell proliferative responses were analysed and it was noted
292that whilst DLN cells from mice that had received the airway
293inﬂammation protocol (OVA and OVA + ES-62 groups) showed ele-
294vated basal levels of proliferation relative to those from PBS (con-
295trol) or ES-62 groups (⁄⁄⁄P < 0.001; Fig. 2A), stimulation with OVA
296ex vivo strongly enhanced this proliferation (⁄P < 0.05 for OVA
297groups and ⁄⁄⁄P < 0.001 for OVA + ES-62 groups) but there were
298no signiﬁcant differences found between the responses of the
299OVA and OVA + ES-62 groups. ES-62 treatment alone had little ef-
300fect on cytokine production in DLN cells (Fig. 2B–F), however, and
301consistent with OVA-induced inﬂammation reﬂecting a Th2 phe-
302notype, IL-4, IL-5, IL-13 and IL-10 production was detected in cells
303from mice undergoing OVA-induced airway inﬂammation and this
304was found to be reduced in cells from such mice exposed to ES-62
305in vivo (Fig. 2B–E). Conversely, exposure to ES-62 did not suppress
306OVA-speciﬁc IFNc production (Fig. 2F). To support these ﬁndings of
307suppression of Th2 responses, we undertook an experiment mea-
308suring cytokine levels in serum samples and whilst the low levels
309of IL-5 detected in mice from the OVA group were signiﬁcantly ele-
310vated relative to the mice treated with PBS or ES-62 alone, the lev-
311els in the OVA + ES-62 group were not signiﬁcantly different from
312the control groups (Fig. 2G). However, serum levels of IL-4, IL-10,
313IL-13 and IFNc in all groups were found to be below the detection
314level of the assay in use. It was also not possible to detect eotaxin.
315The chemokines, MCP-1, MIG (CXCL9) and MIP-1a, and the growth
316factor, FGF, which have been implicated in the inﬂammation and
317increased angiogenesis associated with remodelling in asthma
318(Linden, 2003; Kolls and Linden, 2004; Havaux et al., 2005; Bosse
319et al., 2006; Feltis et al., 2006) were detected; however, serum
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320 levels of these inﬂammatory mediators were not found to be sig-
321 niﬁcantly different amongst the four treatment groups (results
322 not shown). The Th2-suppressive effects of ES-62 on OVA-treated
323 mice were Ag-speciﬁc because they were not mirrored in the mito-
324 gen (ConA)-induced proliferation and cytokine responses of DLN
325 cells (results not shown).
326 3.3. ES-62 treatment inhibits IgE production
327 As antibodies, especially those of the signature Th2 isotype, IgE,
328 have great inﬂuence in directing and enhancing the inﬂammatory
329 immune response in allergic airway disease (Busse and Neaville,
330 2001; Busse and Lemanske, 2001), it was next determined whether
331 the anti-inﬂammatory action of ES-62 was reﬂected by a change in
332 the antibody proﬁle in vivo. Thus, sera from all groups of mice were
333 analysed in vitro for total IgE and OVA-speciﬁc IgG1, IgG2a and IgE
334 content. Whilst IgE levels were elevated in the OVA, relative to the
335 control and ES-62 groups (Fig. 3A, B), this elevation in antibody
336 production was signiﬁcantly inhibited by prophylactic treatment
337 with ES-62 (OVA + ES-62 group) (P < 0.001 for both total and
338 OVA-speciﬁc IgE). However, analysis of sera IgG demonstrated that
339 levels of OVA-speciﬁc IgG1 and IgG2a antibody isotypes in mice
340 that had received the OVA administration protocol were not inﬂu-
341 enced by exposure to ES-62 (Fig. 3C, D). Consistent with the ob-
342 served reduction in serum IgE levels, lower levels of IgE
343 expression could be detected in DLN cells from OVA + ES-62, rela-
344 tive to OVA, mice (Fig. 3E).
345 3.4. Exposure to ES-62 in vivo modulates the Th1/Th2 balance in OVA-
346 induced airway inﬂammation
347 To investigate whether ES-62 was suppressing the development
348 of Th2 responses in OVA-induced airway inﬂammation by induc-
349 tion of regulatory T (Treg) cells, DLN tissue sections were stained
350 for expression of the signature Treg, Th1 and Th2 transcription fac-
351 tors, FoxP3, Tbet and GATA3, respectively (Fig. 3F), and imaged and
352 quantitatively analysed by LSC (Adams et al., 2004; Morton et al.,
3532007). Consistent with the observed inhibition of Th2 responses,
354the number of cells expressing GATA3 was reduced essentially to
355zero following ES-62 exposure but this did not appear to reﬂect
356suppression by Treg cells as the number of FoxP3 positive cells
357was also slightly reduced in the DLN cells from ES-62-treated mod-
358el mice (Fig. 3F). These data were corroborated by ﬂow cytometric
359analysis of DLN cells from an independent experiment that showed
360no substantial differences in the levels of Foxp3+ CD4+Tregs
361amongst the different treatment groups (Fig. 3G) or in production
362of the Treg effector cytokine, IL-10, by DLN cells (Fig. 3H). By con-
363trast, however, there was an appearance of cells expressing Tbet in
364DLN sections from the ES-62-treated OVAmodel mice (Fig. 3F) sug-
365gesting that ES-62 might act by resetting the Th1/Th2 balance in
366OVA-induced airway inﬂammation. Likewise, data from an inde-
367pendent experiment showed that exposure to ES-62 in vivo re-
368sulted in increased levels of spontaneous (Fig. 3I) IFNc
369production by DLN cells from mice undergoing OVA-induced air-
370way inﬂammation, with the OVA + ES-62 group exhibiting an
371approximately twofold increase in the small proportion of DLN
372cells producing IFNc, relative to those from OVA mice, which
373exhibited comparable levels to those of naïve animals. Consistent
374with our previous ﬁndings that exposure to ES-62 alone induces
375a weak Th2 phenotype in naïve healthy mice (Whelan et al.,
3762000; Marshall et al., 2005), the lowest levels of spontaneous
377IFNc-producing cells were observed in DLNs from the ES-62 group.
378Moreover, the OVA + ES-62 group contained the highest percent-
379age of IFNc-producing cells (and the highest expression of IFNc
380within cells) following stimulation with PMA plus ionomycin
381(Fig. 3J) whilst the lowest proportion of such cells was found in
382the DLN from the control (PBS) group of mice.
3833.5. Neutralising anti-IFNc antibodies inhibit the protection against
384airway inﬂammation afforded by ES-62
385To address whether the ES-62 mediated stimulation of IFNc
386production played a role in the protection afforded by the helminth
387product by resetting the Th1/Th2 balance, the effect of neutralising
Fig. 1. The phosphorylcholine-containing glycoprotein, ES-62, inhibits eosinophilia, neutrophilia and lymphocyte inﬁltration of the lung in the murine ovalbumin (OVA)-
induced airway inﬂammation model. Differential eosinophil (A), neutrophil (B), lymphocyte (C), macrophage (D) and total (E) bronchoalveolar lavage ﬂuid (BALF) cell counts
in individual mice from each of the four treatment groups where, for A–D, n = 32 for PBS; n = 22 for ES-62; n = 51 for OVA and n = 38 for OVA + ES-62 groups and for E, n = 42
for PBS; n = 24 for ES-62; n = 59 for OVA and n = 44 for OVA + ES-62 groups. The bar represents the median value of the group and ⁄P 6 0.05 or ⁄⁄P 6 0.01 for OVA compared
with OVA + ES-62 groups.
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Fig. 2. In vivo treatment with the phosphorylcholine-containing glycoprotein, ES-62, inhibits draining lymph node (DLN) cell antigen-speciﬁc Th2 cytokine production but
not antigen-speciﬁc proliferation ex vivo. Lung DLN (thoracic and cervical) cells from individual mice within each in vivo treatment group were pooled and cultured with
medium alone or ovalbumin (OVA) (500 lg/ml) for 72 h. Cell proliferation was measured by [3H] thymidine uptake and data (A) are expressed as mean ± S.D. (n = 3 replicate
cultures) and are from one experiment representative of two. Culture supernatants IL-4 (B), IL-5 (C), IL-13 (D), IL-10 (E) and IFNc (F) were measured for each group and data
are expressed as mean concentrations ± S.D., n = 3 replicate cultures, where ⁄⁄⁄P < 0.001, apart from IL-4 and IFNcwhich were measured as duplicate samples by Luminex, and
represent single data sets representative of at least two independent experiments apart from IL-13 which was only measured in a single experiment to corroborate the
decrease in the very low levels of IL-4 observed in that model. (G) The mean values of triplicate serum values from individual mice (n = 6) are shown where the bar represents
the mean of the group and the OVA, but not OVA + ES-62, group shows signiﬁcantly elevated levels of IL-5 (⁄P 6 0.05) relative to the PBS and ES-62 control groups.
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Fig. 3. Exposure to the phosphorylcholine-containing glycoprotein, ES-62, in vivo does not modulate ovalbumin (OVA)-induced elevation of IgG1 and IgG2a but inhibits IgE
and suppresses Th2 cells. Serum samples from each mouse were obtained on day 28. Samples were analysed by ELISA for OVA-speciﬁc IgE (A) and total IgE (B), at 1/80 and 1/
200 dilutions, respectively, and OVA-speciﬁc IgG1 (C) and IgG2a (D) over the full titration range where data for each group are presented as the mean ± S.E.M. (n = 6 mice/
group) and ⁄⁄⁄P < 0.001, OVA + ES-62 compared with the OVA group. The data are from one experiment representative of two. In E, draining lymph nodes (DLN) cells from
each of the four treatment groups were stained for expression of IgE. (F) DLN sections from OVA and OVA + ES-62 groups were stained for B220+ B cells, CD3+ T cells and for
the indicated transcription factor (either GATA3, FoxP3 or Tbet) and the transcription factor positive cells were quantiﬁed within the T cell regions. Exemplar tissue maps
from a single experiment of DLNs from OVA and OVA + ES-62 groups displaying the relevant distribution of such transcription factor positive cells (red) within the T cell
paracortical region (white) surrounded by B220+ B cells (blue) and their quantitation of numbers of the relevant transcription factor positive T cells by laser scanning
cytometry (LSC) are shown, together with an exemplar relocated image of a portion of the section from the OVA group where Foxp3 is stained in red and CD3, green (F). In an
independent experiment, the proportions of FoxP3-expressing unstimulated CD4+ T cells from the DLN of pooled mice from the four treatment groups are shown, with the
percentage of cells in the FoxP3+CD4+ quadrant annotated to the right of the plots (G). Pooled DLN cells from the four treatment groups were cultured with medium (I) or
phorbol 12-myristate 13-acetate (PMA) plus ionomycin (IONO) (H, J) in the presence of Brefeldin A before staining for intracellular expression of IL-10 (H) or IFNc (I, J) prior to
FACS analysis: cytokine expression (y-axis) was plotted against side scatter (x-axis) and the percentage of DLN cells in the cytokine positive gate is shown and annotated to
the right of the plots. (J) The Mean Fluorescence Intensity (MFI) values for IFNc production for the four treatment groups are PBS: 24,701; ES-62: 21,915; OVA: 23,439 and
OVA + ES-62: 27,596. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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388 anti-IFNc antibodies (or control IgG) during OVA-induced airway
389 inﬂammation was investigated in two further independent exper-
390 iments. It was noted (Fig. 4A) that a signiﬁcantly greater propor-
391 tion of PMA plus ionomycin-stimulated DLN cells from the
392 OVA + ES-62, but not OVA, group treated with the control IgG ex-
393 pressed IFNc than those from the PBS control group. However, this
394 was not found to be the case in the presence of the neutralising
395 anti-IFNc antibodies (Fig. 4A). The expanded population of IFNc-
396 producing cells observed in the OVA + ES-62 mice (Fig. 3I, J) re-
397 ﬂected increases in both IFNc-producing CD4+ (Fig. 4B, C) and
398 CD8+ (Fig. 4D, E) T cell populations. Analysis of the data from the
399 two neutralising antibody studies showed that whilst the propor-
400 tion (Fig. 4F) and number (Fig. 4G) of PMA plus ionomycin-stimu-
401 lated CD4 DLN cells (predominantly CD8+ T cells) producing IFNc
402 were signiﬁcantly higher in the IgG-treated OVA + ES-62, but not
403 OVA, group relative to the PBS control group, this effect was abol-
404 ished by exposure to the neutralising anti-IFNc antibodies. How-
405 ever, the proportion (Fig. 4H) of CD4+ DLN cells expressing IFNc
406 following stimulation with PMA plus ionomycin was not signiﬁ-
407 cantly different in the IgG-treated OVA + ES-62 group, relative to
408 the OVA group, suggesting that the immunomodulatory IFNc elic-
409 ited by ES-62 was predominantly derived from CD4 DLN cells,
410 which are likely to be Tbet+CD8+ T cells (Szabo et al., 2002). Collec-
411 tively, these data indicate that the neutralising anti-IFNc antibod-
412 ies were effective in vivo and suggest that blocking of this cytokine
413abrogates the resetting of the Th1/Th2 phenotype observed in
414OVA + ES-62 mice.
415Importantly, therefore, and supportive of a role for ES-62 stim-
416ulated IFNc in protecting against OVA-induced airway inﬂamma-
417tion, the OVA + ES-62 group of mice treated with neutralising
418anti-IFNc antibodies showed elevated levels of neutrophil
419(Fig. 5A), macrophage (Fig. 5B) and lymphocyte (Fig. 5C) inﬁltration
420of the BALF relative to those treated with control IgG. Moreover,
421although it did not reach statistical signiﬁcance, the level of esoin-
422ophils also increased (Fig. 5D). In addition, analysis of lung pathol-
423ogy revealed higher levels of cellular inﬁltration and airway
424remodelling in the OVA + ES-62 group treated with the neutralising
425antibody, relative to the isotype Control group (Fig. 5E).
426It appeared that the effect generated by anti-IFNc treatment re-
427ﬂected, at least in part, that this cytokine does indeed act to reset
428the Th1/Th2 balance as although, as expected, ES-62-treated mice
429induced more IL-4-producing DLN cells than those of the control
430PBS group, the OVA + ES-62 group exhibited a lower proportion
431of IL-4-producing DLN cells than of the OVA group (Fig. 6A) in re-
432sponse to stimulation with PMA plus ionomycin. Moreover, analy-
433sis of data for individual mice from the two neutralising antibody
434experiments revealed that whilst the number of spontaneously-
435(Fig. 6B) and PMA plus ionomycin-stimulated (Fig. 6C) IL-4-pro-
436ducing DLN cells was signiﬁcantly elevated in the OVA + IgG, but
437not OVA + ES-62 + IgG, group relative to the control PBS mice, in
Fig. 4. Exposure to the phosphorylcholine-containing glycoprotein, ES-62, in vivo increases CD4 and CD8 IFNc responses during murine ovalbumin (OVA)-induced airway
inﬂammation. (A) The proportion of draining lymph node (DLN) cells expressing IFNc following stimulation with phorbol 12-myristate 13-acetate (PMA) plus ionomycin in
the indicated treatment groups by individual mice (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled
from two independent experiments). The bar represents the mean of the group and the OVA + ES-62 + IgG, but not OVA + IgG, group is signiﬁcantly different from the PBS
group (grey ⁄⁄P 6 0.01). In an independent experiment, the cytokine expression (y-axis) by cells from pooled DLN from the indicated groups was analysed and the proportions
of IFNc-producing cells in the lymphocyte gate of DLN cells from mice from the OVA and OVA + ES-62 groups that were CD4+ (B, C) or CD8+ (D, E) following stimulation with
medium (B, D) or PMA plus ionomycin (C, E) are shown. The proportions (F) and numbers (G) of PMA plus ionomycin-stimulated CD4 cells expressing IFNc in the DLN of
individual mice from the indicated groups (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from
two independent experiments) are shown where the bar represents the mean of the group and the OVA + ES-62 + IgG group demonstrates signiﬁcantly elevated levels of IFNc
production relative to the PBS control group (where ⁄P 6 0.05). (H) The proportions of PMA plus ionomycin-stimulated CD4+ cells expressing IFNc in the DLN of individual
mice from the indicated groups (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from two
independent experiments) are shown where the bar represents the mean of the group and no signiﬁcant differences are detected.
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438 the presence of neutralising anti-IFNc antibodies the OVA + ES-62
439 group exhibited signiﬁcantly higher numbers of such cells
440 (Fig. 6B, C). A similar pattern of IL-4 production was shown for both
441 CD4 (Fig. 6D, spontaneous; Fig. 6E, PMA plus ionomycin) and
442 CD4+ T cells (Fig. 6F, PMA plus ionomycin), the latter subtype spon-
443 taneously expressing IL-4 at signiﬁcantly higher levels in response
444 to anti-IFNc treatment (Fig. 6G), than to treatment with control
445 IgG.
446 3.6. ES-62-mediated resetting of the Th1/Th2 balance in OVA-induced
447 airway inﬂammation is associated with suppression of Th17/IL-17
448 responses
449 Members of the IL-17 family of cytokines, including IL-17
450 (IL-17A and IL-17F) and IL-25 (IL-17E) have recently been reported
451 to play key roles in promoting Th2 polarisation and eosinophil
452 (Dias and Banerjee, 2012; Murdock et al., 2012), neutrophil (Iwak-
453ura et al., 2011) and macrophage recruitment (Barin et al., 2012)
454leading to AHR (Hellings et al., 2003; Linden, 2003; Kawaguchi
455et al., 2004; Schnyder-Candrian et al., 2006; Pichavant et al.,
4562008; Traves and Donnelly, 2008; Wang and Liu, 2008; Lajoie
457et al., 2010; Wang et al., 2010; Iwakura et al., 2011). In addition,
458Th17 cells have been shown to counter-regulate Th1 responses
459(Durrant and Metzger, 2010; Jager and Kuchroo, 2010). Thus it
460was investigated whether ES-62-mediated suppression of patho-
461logical Th2- and induction of counter-regulatory IFNc-responses
462correlated with targeting of IL-17 production (Fig. 7). Analysis of
463the small populations of IL-17-producing DLN cells indicated that
464whilst those from the PBS, ES-62 and OVA + ES-62 groups exhibited
465comparable proportions of DLN cells spontaneously producing IL-
46617, this was slightly elevated in the OVA group (Fig. 7A). Similarly,
467the OVA mice exhibited the highest levels of such cells in response
468to PMA plus ionomycin but this population was substantially re-
469duced in the OVA mice exposed to ES-62 in vivo (Fig. 7B). Such
Fig. 5. Neutralising anti-IFNc antibodies prevent ES-62-mediated protection against cellular inﬁltration in murine ovalbumin (OVA)-induced airway inﬂammation.
Differential neutrophil (A), macrophage (B), lymphocyte (C) and eosinophil (D) bronchoalveolar lavage ﬂuid (BALF) cell counts for individual mice in each of the indicated
treatment groups (PBS, n = 8; OVA + IgG, n = 10; OVA + ES-62 + IgG, n = 8; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 10; pooled from two independent
experiments) are shown where the bar represents the median of the group and black ⁄P 6 0.05 and ⁄⁄P 6 0.01 are for OVA + ES-62 + IgG compared with OVA + ES-62 + anti-
IFNc groups whilst grey ⁄⁄P 6 0.01 and ⁄⁄⁄P 6 0.001 are for PBS compared with the indicated treatment group. (E) Representative H & E sections from the OVA + ES-62 + IgG
(n = 3 mice) and the OVA + ES-62 + anti-IFNc (n = 3 mice) groups. Images were captured using an Olympus BX41 microscope mounted with an Olympus U-CMAD3 camera
and Cell-B2.0 software. Images are at 10 magniﬁcation and include automatic yellow scale bar (200 lm) at the bottom right corner of image.
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470 suppression reﬂected reductions in the proportions of IL-17-pro-
471 ducing cd, CD4 and CD8 T cells and RORct-expressing DLN cells,
472 including RORct+CD4+ T cells (Fig. 7C and results not shown). In-
473 deed, the data from the two neutralising antibody experiments
474 showed that whilst mice from the OVA, but not OVA + ES-62, group
475 treated with control IgG exhibited a higher number of DLN cells
476 producing IL-17 than the PBS group, either spontaneously
477 (Fig. 7D, upper panel) or following stimulation with PMA plus ion-
478 omycin (Fig. 7D, lower panel), the OVA + ES-62 group treated with
479 neutralising anti-IFNc antibodies showed signiﬁcantly upregulated
480 responses. Likewise, whilst mice from the OVA, but not OVA + ES-
481 62, group treated with control IgG exhibited higher numbers of
482 CD4 (Fig. 7E) and percentages of Th17 (IL-17+CD4+, Fig. 7F) cells
483 following stimulation with PMA plus ionomycin than the PBS con-
484 trol group, the OVA + ES-62 group treated with neutralising anti-
485 IFNc antibodies again showed signiﬁcantly upregulated responses
486 (Fig. 7E, F). Reﬂecting this, analysis of IL-17 mRNA production by
487 DLN cells in an independent experiment revealed that in vivo
488 exposure to ES-62 reduced the levels found in the OVA group to
489those comparable with levels of IL-17 mRNA found in the PBS or
490ES-62 groups (Fig. 7G) and although the levels observed were very
491low, this was reﬂected by reduced levels of OVA-speciﬁc IL-17 re-
492call responses by DLN cells ex vivo in a further separate experiment
493(Fig. 7H). Such suppression of Th17 responses reﬂected, at least in
494part, a reduction in the ability of mice to prime Th17 responses as
495bmDCs from OVA + ES-62 mice induced signiﬁcantly reduced OVA-
496speciﬁc Th17 responses relative to those from the OVA group
497(Fig. 7I). This suppression of IL-17 responses is not restricted to
498the DLN cells but is also apparent at the site of inﬂammation as
499RT-PCR analysis indicated reductions in the levels of IL-4 and IL-
50017, but not IFNc, mRNA in the lungs of mice from the OVA + ES-
50162, relative to the OVA, group of mice (Fig. 7J) in a further indepen-
502dent experiment.
503Collectively therefore, the results outlined above provide sup-
504port for the proposal that ES-62 is acting to suppress Th17/Th2-
505associated airway inﬂammation and consequent pathology, not
506by inducing Treg cells but by inducing counter-regulatory IFNc re-
507sponses to reset the Th1/Th2/Th17 balance.
Fig. 6. Neutralising anti-IFNc antibodies modulate IL-4 responses in ES-62-treated mice undergoing ovalbumin (OVA)-induced airway inﬂammation. Draining lymph node
(DLN) cells from the four indicated treatment groups were cultured with phorbol 12-myristate 13-acetate (PMA) plus ionomycin in the presence of Brefeldin A before staining
for intracellular expression of IL-4 prior to FACS analysis: cytokine expression (y-axis) was plotted against side scatter (x-axis) and the percentage of DLN cells in the cytokine
positive gate shown and annotated to the right of the plot labels (A). Data pooled from two further independent experiments show the numbers (B–F) and Mean Fluorescence
Intensity (MFI) (G) of spontaneously- (B, D, G) and PMA plus ionomycin-stimulated (C, E, F) IL-4-producing DLN (B, C), CD4 DLN (D, E) and CD4+ DLN (F, G) cells. The bar
represents the mean value of the group where black ⁄P 6 0.05 represents the difference between the OVA + ES-62 + IgG compared with the OVA + ES-62 + anti-IFNc groups
whilst grey ⁄P 6 0.05, ⁄⁄P 6 0.01 and ⁄⁄⁄P 6 0.001 are for PBS compared with indicated treatment group (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-
IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from two independent experiments).
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508 4. Discussion
509 It was previously shown that prophylactic exposure to ES-62, a
510 PC-containing glycoprotein secreted by the ﬁlarial nematode A.
511viteae, suppresses OVA-induced allergic airway disease in the
512mouse (Melendez et al., 2007). Although this protection was asso-
513ciated with desensitisation of mast cell responses, ES-62 was also
514shown to suppress the Th2 phenotype of the allergic response, as
Fig. 7. The phosphorylcholine-containing glycoprotein, ES-62, suppresses IL-17 responses in murine ovalbumin (OVA)-induced airway inﬂammation. Pooled draining lymph
node (DLN) cells from the four indicated treatment groups were cultured with medium (A) or phorbol 12-myristate 13-acetate (PMA) plus ionomycin (B) in the presence of
Brefeldin A before staining for intracellular expression of IL-17 prior to FACS analysis: cytokine expression (y-axis) was plotted against side scatter (x-axis) and the percentage
of DLN in the cytokine positive gate shown and annotated to the right of the plots. RORct -(C) expressing unstimulated CD4+ T cells from the DLN of pooled mice from the four
treatment groups are shown. The numbers (D) of spontaneously (upper; (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-IFNc, n = 10 and OVA + ES-
62 + anti-IFNc, n = 9; pooled from two independent experiments)) and PMA plus ionomycin-stimulated (lower; (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 9;
OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from two independent experiments)) IL-17 producing DLN cells and the numbers of CD4 DLN cells (E) and
proportions of IL-17-producing CD4+ cells (F) from PMA plus ionomycin-stimulated DLN cells from individual mice (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 9;
OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from two independent experiments) are presented; the bar represents the mean value of the group and
grey ⁄P 6 0.05 shows the difference between the PBS and indicated treatment group. In an independent experiment (G, I), the levels of IL-17 mRNA (against a glyceraldehyde
3-phosphate dehydrogenase (GAPDH) reference) in the pooled DLN cells from the four indicated treatment groups are shown, normalised to the levels found in the control
PBS group (G). (H) The levels of IL-17 detected by Luminex following stimulation of pooled DLN cells from mice in each group with medium or OVA (500 lg/ml) in a further
independent experiment are shown and where ⁄⁄⁄P 6 0.001 for triplicate samples. In (I), pooled bone marrow-derived dendritic cells (bmDCs) from OVA and OVA + ES-62
mice were pulsed with OVA peptide on day 7 and cocultured with DO11.10Tg CD4+CD62L+ T cells for 72 h before analysing the levels of IL-17 production in culture
supernatants by ELISA. The data are presented as the mean ± S.D. where ⁄⁄P < 0.01, OVA compared with OVA + ES-62 at 30 nM of OVA peptide and ⁄⁄⁄P < 0.001, OVA compared
with OVA + ES-62 at 300 nm of OVA peptide in one experiment. In a further independent experiment, (J), the levels of IL-4, IFNc and IL-17 mRNA (against a GAPDH reference)
in the lungs from the OVA + ES-62 group (grey bars) are shown, normalised to the levels found in the OVA group (black bars).
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515 measured by a reduction in eosinophilia and IL-4 levels in the
516 lungs. We now show that ES-62 suppresses the lung inﬁltration
517 by a heterogeneous population of cells, particularly neutrophils, a
518 phenotype that is associated with severe asthma and is generally
519 refractory to conventional anti-inﬂammatory therapies, including
520 steroids (Ito et al., 2008; Iwakura et al., 2011; Yang et al., 2012).
521 Consistent with the observed inhibition of cells inﬁltrating the
522 lungs, we also found that exposure to ES-62 suppressed IL-17 re-
523 sponses, which have recently been shown to play key roles in
524 recruitment of eosinophils, neutrophils and macrophages as well
525 as in the promotion of Th2 polarised inﬂammation and develop-
526 ment of severe asthma (Lajoie et al., 2010; Wang et al., 2010; Iwak-
527 ura et al., 2011; Barin et al., 2012; Dias and Banerjee, 2012). Such
528 protection against Th2/Th17-associated airway inﬂammation did
529 not reﬂect induction of Treg responses (no increased IL-10 or Foxp3
530 expression) but rather a switch in priming towards increased Tbet
531 expression and IFNc production. Further support for ES-62 sup-
532 pressing pathogenic Th2/Th17 responses by inducing counter-reg-
533 ulatory IFNc responses (Durrant and Metzger, 2010; Jager and
534 Kuchroo, 2010) was provided by our studies showing that neutral-
535 ising anti-IFNc antibodies blocked the protection against airway
536 inﬂammation afforded by ES-62, in terms of cellular inﬁltration
537 of the lungs as well as airway remodelling, and that this loss of pro-
538 tection was accompanied by elevated Th2 and Th17 responses.
539 The anti-inﬂammatory mechanism that is employed by ES-62
540 was compared with that associated with some other helminths
541 and their products. It appears to be quite distinct from the ap-
542 proach utilised by the gastrointestinal (GI) nematode, Heligmo-
543 somoides polygyrus, which can inhibit OVA-induced airway
544 inﬂammation in mice via the induction of a Treg cell population
545 (Wilson et al., 2005). Moreover, there are a number of differences
546 observed between the immunomodulatory effects of an H. polygy-
547 rus infection and ES-62 when affording protection. For example,
548 the GI nematode only inhibited production of Th2 effector cyto-
549 kines (IL-5/IL-13) whereas ES-62 also had an inhibitory effect on
550 a cytokine that facilitates Th2 responses, IL-4. This is likely to ex-
551 plain why, unlike in the H. polygyrus study, we observed a decrease
552 in IgE levels. We also could not ﬁnd any evidence of increased lev-
553 els of Treg cells as evidenced by FoxP3 expression or production of
554 IL-10 in DLN cell cultures from ES-62 exposed animals although
555 this regulatory cytokine is also not the principal facilitator of the
556 protective effects of H. polygyrus (Wilson et al., 2005). It is worth
557 emphasising at this point that our present data are consistent with
558 our previous work indicating that there is little evidence that ES-62
559 induces any form of Treg population (Marshall et al., 2005). In
560 agreement with our observations, recent data (McSorley et al., in
561 press) reported a lack of expansion of Tregs upon treatment of
562 allergic mice with H. polygyrus excretory–secretory (HES) products,
563 even though administration of HES products at the sensitisation
564 stage signiﬁcantly diminished numbers of eosinophils and neutro-
565 phils in BAL and macrophages in the lung. In this respect therefore,
566 the effects of HES products are similar to those afforded by ES-62.
567 Importantly, however, treatment with HES products abolished
568 OVA-induced IFNc, in addition to downregulating IL-4, IL-5 and
569 IL-13 production, a ﬁnding which appears to rule out the possibil-
570 ity that HES and ES-62 might share a commonmechanism of action
571 in suppression of allergic airway inﬂammation.
572 The immunomodulatory effects being observed with ES-62 are
573 also comparable to those describedwhen AHR to OVAwas inhibited
574 by an extract of the GI nematode, Ascaris suum (Lima et al., 2002).
575 Here, each of IL-4 and IL-5 in BALF, and IgG1 and IgE in serum was
576 reduced. As with ES-62 (Melendez et al., 2007), airway hyper-reac-
577 tivity tomethacholinewas also inhibited in thismodel system (Lima
578 et al., 2002). One difference from the A. suum study was that we did
579 not see a reduction in serum IgG1butwepreviously showeda lack of
580 a relationship between the ability of ES-62 to induce IL-4 and pro-
581mote IgG1 responses to OVA (Marshall et al., 2005). A decrease in
582IgE without a decrease in IgG1 could perhaps reﬂect the activity of
583IL-10 (Jeannin et al., 1998) but as mentioned above we could ﬁnd
584no evidence for increased IL-10 in our study. More recently, another
585ﬁlarial nematode-derivedmolecule, cystatin, has been found to pro-
586tect against OVA-induced airway hyper-reactivity, showingmany of
587theproperties of ES-62 in reducingeosinophilia, IgE and IL-4 (Schno-
588eller et al., 2008). Although similar to ES-62, the effect of this mole-
589cule does not appear to be due to induction of Tregs, it differs from
590ES-62 in relying on IL-10 for some activities. In particular, whilst a
591role for IL-10-producing macrophages is reported in the cystatin
592study (Schnoeller et al., 2008), we have found that the spontaneous
593secretion of IL-10 frommacrophages derived frommicewith airway
594disease was reduced in the group exposed to ES-62 (results not
595shown). We also found IL-10 responses to be suppressed by ES-62
596throughout this current study and although such effects are perhaps
597initially surprising, recent ﬁndings suggesting that IL-4 and IL-10 are
598essential for pulmonary arterial remodelling in response to inhaled
599Aspergillus allergen in a mixed Th1/Th2/Th17 microenvironment
600(Shreiner et al., 2012) may suggest that this suppression of IL-10
601contributes to the protection afforded by the helminth product.
602Whilst the immunoregulatory mechanisms involved have not
603been fully delineated, as mentioned earlier, ES-62 appears to act,
604at least in part, by resetting the Th1/Th2/Th17 balance by inducing
605a switch in priming towards a Th1-like phenotype (relative in-
606crease in IFNc and induction of Tbet expression, involving both
607CD4 and CD8 T cells). Whilst Tbet-expressing induced Tregs have
608been reported (Anderson et al., 2006; Cobbold, 2006), it is unlikely
609that the induction of Tbet expression by ES-62 reﬂects the genera-
610tion of such induced Tregs as these have also been reported to
611mediate their effects, at least in part, via IL-10 production which
612is, as noted earlier, reduced in the ES-62-treated groups. Moreover,
613recent analysis of Tbet/ mice has revealed that dysfunction of
614Tbet may be involved in the pathogenesis of allergic airway disease
615and that Tbet+CD4+ cells can inhibit Th2-mediated eosinophilia
616(Fujiwara et al., 2007). Consistent with this, expression levels of
617Tbet appear to be reduced in the airways of asthmatic patients
618(Finotto et al., 2002) and polymorphisms in this transcription fac-
619tor have been associated with airway inﬂammation and hyper-
620responsiveness (Raby et al., 2006; Munthe-Kaas et al., 2008; Dur-
621rant and Metzger, 2010). Collectively, therefore, these ﬁndings pro-
622vide a potential rationale for how resetting of the Th1/Th2 balance
623associated with increased Tbet and IFNc expression by ES-62 can
624suppress airway inﬂammation.
625Given that Th17 cells can counter-regulate Th1 development
626and that IL-17 family members (IL-17A, F and IL-25 (IL-17E) have
627been shown to promote allergic airway inﬂammation (Linden,
6282003; Kawaguchi et al., 2004; Traves and Donnelly, 2008; Wang
629and Liu, 2008; Durrant and Metzger, 2010; Jager and Kuchroo,
6302010), a potential mechanism for the induction of counter-regula-
631tory IFNc production is suggested by our ﬁndings that the ES-62-
632driven switch in the Th1/Th2 balance was accompanied by a de-
633crease in the proportion of DLN cells producing IL-17 and in the
634ability of bmDCs from ES-62-treated mice to prime Th17 re-
635sponses. Intriguingly, we have recently demonstrated that the abil-
636ity of ES-62 to protect against IL-17-dependent Th1-associated
637autoimmune inﬂammation in the collagen-induced mouse model
638of arthritis reﬂected targeting of a complex (cd T cell, DC and
639Th17 interactions) cellular network in which ES-62 suppressed
640both initiation of, and maintenance of ongoing, IL-17 responses
641(Pineda et al., 2012). Indeed, the IL-17-producing CD4 DLN cell
642population targeted by ES-62 in this present study may include a
643similar population of IL-17-producing cd T cells modulated by
644the helminth product.
645Thus, ES-62 may target IL-17 as a mechanism to suppress either
646Th1 or Th2 pathology by resetting the Th1/Th2 balance. Support for
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647 this proposal in terms of Th2 allergic airway inﬂammation is pro-
648 vided by studies demonstrating that the extent of AHR following
649 exposure to methacholine correlates with the levels of IL-17 (Bar-
650 czyk et al., 2003; Kolls et al., 2003; Durrant and Metzger, 2010) and
651 consistent with this, we have found that exposure to ES-62 in vivo
652 substantially suppresses AHR (Melendez et al., 2007). Moreover,
653 studies on IL-17A- or IL-17RA-deﬁcient mice showed decreased
654 induction of OVA-speciﬁc T cells, reduced eosinophilic inﬂamma-
655 tion and lower levels of serum IgE (Nakae et al., 2002; Schnyder-
656 Candrian et al., 2006; Durrant et al., 2009; Durrant and Metzger,
657 2010) and may reﬂect our ﬁndings that treatment of the
658 OVA + ES-62 group with neutralising anti-IFNc antibodies results
659 in elevated levels of Th2 cells (perhaps reﬂecting the increase in
660 lymphocyte inﬁltration of the BALF) as well as the increased neu-
661 trophil and macrophage recruitment more normally associated
662 with elevated Th17 responses. Of particular interest, therefore, gi-
663 ven our ﬁndings with respect to ES-62-mediated induction of Tbet
664 and resetting of the Th1/Th2 balance, OVA-induced airway inﬂam-
665 mation is predominantly Th17-mediated in Tbet-deﬁcient animals
666 and this inﬂammation can be suppressed by treatment with IL-12
667 during the challenge phase (Durrant et al., 2009; Durrant and
668 Metzger, 2010).
669 However, it should be noted that IL-17A may also act in sensi-
670 tised mice to dampen the allergic response by inhibiting chemo-
671 kine production, eosinophilia and bronchial hyperactivity
672 (Hellings et al., 2003; Schnyder-Candrian et al., 2006) and that hu-
673 man hyper-IgE syndrome is associated with a failure in IL-17 pro-
674 duction by T cells (Ma et al., 2008; Milner et al., 2008). Moreover,
675 IFNc-producing Th1 cells have been implicated in the development
676 of severe macrophage-dependent, steroid-resistant asthma (Yang
677 et al., 2009). However, these pathogenic effects of IFNc are entirely
678 dependent on crosstalk with endotoxin-driven TLR4/MyD88 pro-
679 inﬂammatory signalling and we previously showed that ES-62 sub-
680 verts TLR4/MyD88 (and TLR2/TLR9 but not TLR3 which is MyD88
681 independent) signalling to an anti-inﬂammatory phenotype and
682 suppresses MyD88 expression during Th17 development (Good-
683 ridge et al., 2005; Melendez et al., 2007; Pineda et al., 2012). Taking
684 these ﬁndings into account, it seems likely that both IFNc and IL-17
685 might exhibit dual pathogenic and protective roles depending on
686 the temporal and microenvironmental context of the response.
687 In conclusion, the ﬁnding that ES-62 acted to suppress Th2 re-
688 sponses of DLNs to heterologous Ag is consistent with the idea that,
689 despite biasing immune responses towards a Th2-like phenotype
690 (Harnett and Harnett, 2010), nematode infections may protect
691 against atopy. Thus, although ES-62 may have a tendency to pro-
692 mote a weak Th2-like immunological phenotype in naïve mice
693 (Houston et al., 2000; Whelan et al., 2000; Marshall et al., 2005),
694 this does not prevent it inhibiting Th2 responses when they are
695 contributing to pathological inﬂammation. ES-62 appears to act
696 to reset the Th1/Th2 balance towards a more ‘‘neutral’’ or anti-
697 pathologic inﬂammatory phenotype by targeting Th17/IL-17. Inter-
698 estingly, this resetting of the Th1/Th2 balance is Ag-speciﬁc as
699 mitogen-induced responses remained unaltered (results not
700 shown and McInnes et al., 2003): thus, ES-62 can act to limit Th1
701 or Th2 pathology induced by chronic inﬂammation whilst allowing
702 the generation of necessary immune responses to remain intact.
703 Collectively, these studies indicate that ES-62 or, more likely, small
704 molecule analogues (patent application number 1214106.5) may
705 have therapeutic potential in asthma, particularly for those sub-
706 types of patients (e.g. smokers, steroid resistant) who are refrac-
707 tory to current treatments.
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